JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Home・Stock List・Lisata Therapeutics

L
Lisata Therapeutics

Closed

4.64 3.11

Buy Sell

Overview

Share price change

24h

Current

Min

4.36

Max

4.75

Key metrics
By Trading Economics
Employees	26

Dividends
By Dow Jones
Next Earnings	26 Feb 2026

Market Stats
By TradingEconomics
Market Cap	15M 35M
Previous open	1.53
Previous close	4.64

Lisata Therapeutics Chart

Past performance is not a reliable indicator of future results.

Related News

3 Feb 2026, 23:11 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 Feb 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 Feb 2026, 23:50 UTC

Market Talk

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 Feb 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 Feb 2026, 23:41 UTC

Acquisitions, Mergers, Takeovers

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 Feb 2026, 23:38 UTC

Earnings

AMD Sales Climb on Help From Data-Center Business -- Update

3 Feb 2026, 23:29 UTC

Acquisitions, Mergers, Takeovers

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 Feb 2026, 23:27 UTC

Acquisitions, Mergers, Takeovers

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 Feb 2026, 23:25 UTC

Acquisitions, Mergers, Takeovers

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 Feb 2026, 23:23 UTC

Acquisitions, Mergers, Takeovers

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 Feb 2026, 23:22 UTC

Acquisitions, Mergers, Takeovers

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 Feb 2026, 23:19 UTC

Market Talk

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 Feb 2026, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

3 Feb 2026, 22:56 UTC

Major Market Movers

Acquisitions, Mergers, Takeovers

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 Feb 2026, 22:40 UTC

Earnings

Amdocs Extends Collaboration With T-Mobile

3 Feb 2026, 22:39 UTC

Earnings

Amdocs 1Q Adj EPS $1.81

3 Feb 2026, 22:39 UTC

Earnings

Amdocs 1Q Rev $1.16B

3 Feb 2026, 22:39 UTC

Earnings

Amdocs 1Q EPS $1.45 >

3 Feb 2026, 22:38 UTC

Earnings

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 Feb 2026, 22:30 UTC

Acquisitions, Mergers, Takeovers

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 Feb 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 Feb 2026, 22:14 UTC

Earnings

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 Feb 2026, 22:13 UTC

Earnings

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 Feb 2026, 22:12 UTC

Earnings

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 Feb 2026, 22:10 UTC

Earnings

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 Feb 2026, 22:10 UTC

Earnings

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 Feb 2026, 22:10 UTC

Market Talk

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 Feb 2026, 22:10 UTC

Earnings

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 Feb 2026, 22:09 UTC

Earnings

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 Feb 2026, 22:09 UTC

Earnings

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Peer Comparison

Price change

Lisata Therapeutics Forecast

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Lisata Therapeutics - Dist in the past 3 months.

Financials

About Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.